S&P 500   3,108.46 (-0.38%)
DOW   27,821.09 (-0.40%)
QQQ   202.15 (-0.60%)
CGC   17.64 (+15.14%)
BABA   182.35 (-1.57%)
GE   11.39 (-0.96%)
T   37.18 (-2.16%)
ACB   2.64 (+12.82%)
F   8.73 (-1.91%)
BAC   32.69 (-0.76%)
DIS   146.93 (-0.98%)
S&P 500   3,108.46 (-0.38%)
DOW   27,821.09 (-0.40%)
QQQ   202.15 (-0.60%)
CGC   17.64 (+15.14%)
BABA   182.35 (-1.57%)
GE   11.39 (-0.96%)
T   37.18 (-2.16%)
ACB   2.64 (+12.82%)
F   8.73 (-1.91%)
BAC   32.69 (-0.76%)
DIS   146.93 (-0.98%)
S&P 500   3,108.46 (-0.38%)
DOW   27,821.09 (-0.40%)
QQQ   202.15 (-0.60%)
CGC   17.64 (+15.14%)
BABA   182.35 (-1.57%)
GE   11.39 (-0.96%)
T   37.18 (-2.16%)
ACB   2.64 (+12.82%)
F   8.73 (-1.91%)
BAC   32.69 (-0.76%)
DIS   146.93 (-0.98%)
S&P 500   3,108.46 (-0.38%)
DOW   27,821.09 (-0.40%)
QQQ   202.15 (-0.60%)
CGC   17.64 (+15.14%)
BABA   182.35 (-1.57%)
GE   11.39 (-0.96%)
T   37.18 (-2.16%)
ACB   2.64 (+12.82%)
F   8.73 (-1.91%)
BAC   32.69 (-0.76%)
DIS   146.93 (-0.98%)
Log in

Advaxis Stock Price, Forecast & Analysis (NASDAQ:ADXS)

$0.38
-0.01 (-2.56 %)
(As of 11/20/2019 04:00 PM ET)
Today's Range
$0.35
Now: $0.38
$0.42
50-Day Range
$0.26
MA: $0.33
$0.49
52-Week Range
$0.21
Now: $0.38
$10.80
Volume6.30 million shs
Average Volume2.26 million shs
Market Capitalization$6.54 million
P/E RatioN/A
Dividend YieldN/A
Beta3.21
Advaxis, Inc, a late-stage biotechnology company, focuses on the discovery, development, and commercialization of Listeria monocytogenes (Lm) technology based antigen delivery product in the United States. It is developing therapies for HPV-related cancers using axalimogene filolisbac (AXAL) for the treatment of head and neck cancer. The company is also developing ADXS-PSA for the treatment of prostate cancer; and ADXS-NEO, an individualized Lm technology antigen delivery product candidate that is designed to create individualized therapies by activating the patient's immune system to respond against multiple mutations or neoantigens. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ADXS
CUSIPN/A
Phone609-452-9813

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$6.06 million
Book Value$5.18 per share

Profitability

Net Income$-66,510,000.00
Net Margins-113.67%

Miscellaneous

Employees58
Market Cap$6.54 million
Next Earnings Date1/9/2020 (Estimated)
OptionableOptionable

Receive ADXS News and Ratings via Email

Sign-up to receive the latest news and ratings for ADXS and its competitors with MarketBeat's FREE daily newsletter.


Advaxis (NASDAQ:ADXS) Frequently Asked Questions

What is Advaxis' stock symbol?

Advaxis trades on the NASDAQ under the ticker symbol "ADXS."

How were Advaxis' earnings last quarter?

Advaxis, Inc. (NASDAQ:ADXS) posted its quarterly earnings results on Monday, September, 9th. The biotechnology company reported ($1.00) earnings per share for the quarter, topping the consensus estimate of ($1.24) by $0.24. The biotechnology company had revenue of $0.01 million for the quarter. Advaxis had a negative return on equity of 67.08% and a negative net margin of 113.67%. View Advaxis' Earnings History.

When is Advaxis' next earnings date?

Advaxis is scheduled to release their next quarterly earnings announcement on Thursday, January 9th 2020. View Earnings Estimates for Advaxis.

What price target have analysts set for ADXS?

1 equities research analysts have issued 1 year target prices for Advaxis' shares. Their forecasts range from $4.00 to $4.00. On average, they expect Advaxis' share price to reach $4.00 in the next year. This suggests a possible upside of 952.6% from the stock's current price. View Analyst Price Targets for Advaxis.

What is the consensus analysts' recommendation for Advaxis?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Advaxis in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Advaxis.

Has Advaxis been receiving favorable news coverage?

News coverage about ADXS stock has been trending somewhat positive recently, according to InfoTrie. The research firm rates the sentiment of press coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Advaxis earned a media sentiment score of 0.9 on InfoTrie's scale. They also gave news coverage about the biotechnology company a news buzz of 1.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View News Stories for Advaxis.

Who are some of Advaxis' key competitors?

What other stocks do shareholders of Advaxis own?

Who are Advaxis' key executives?

Advaxis' management team includes the folowing people:
  • Mr. Kenneth A. Berlin J.D., Pres, CEO & Director (Age 55)
  • Ms. Molly Henderson CPA, CPA, MBA, Exec. VP, CFO & Corp. Sec. (Age 48)
  • Dr. Robert G. Petit, Exec. VP & Chief Scientific Officer (Age 59)
  • Mr. Anthony A. Lombardo, Exec. Officer (Age 70)
  • Dr. Andres A. Gutierrez, Exec. VP & Chief Medical Officer (Age 58)

How do I buy shares of Advaxis?

Shares of ADXS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Advaxis' stock price today?

One share of ADXS stock can currently be purchased for approximately $0.38.

How big of a company is Advaxis?

Advaxis has a market capitalization of $6.54 million and generates $6.06 million in revenue each year. The biotechnology company earns $-66,510,000.00 in net income (profit) each year or ($19.34) on an earnings per share basis. Advaxis employs 58 workers across the globe.View Additional Information About Advaxis.

What is Advaxis' official website?

The official website for Advaxis is http://www.advaxis.com/.

How can I contact Advaxis?

Advaxis' mailing address is 305 COLLEGE ROAD EAST, PRINCETON NJ, 08540. The biotechnology company can be reached via phone at 609-452-9813 or via email at [email protected]


MarketBeat Community Rating for Advaxis (NASDAQ ADXS)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  344 (Vote Outperform)
Underperform Votes:  363 (Vote Underperform)
Total Votes:  707
MarketBeat's community ratings are surveys of what our community members think about Advaxis and other stocks. Vote "Outperform" if you believe ADXS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ADXS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/20/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel